Clinical Cancer Informatics

From the *Department of Medicine, Division of Medical Oncology, Duke University School of Medicine, Durham, NC; †Department of Palliative and Supportive Services, Division of Medicine, Flinders University, Bedford Park, South Australia, Australia; and ‡Department of Medicine and Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY. Conflicts of Interest and Sources of Funding: A.P.A has received research funding from the U.S. National Institutes of Health, U.S. Agency for Healthcare Research and Quality, Robert Wood Johnson Foundation, Pfizer, Eli Lilly, Bristol Meyers Squibb, Helsinn Therapeutics, Amgen, KangLaiTe, Alexion, BioVex, DARA Therapeutics, Novartis, and Mi-Co. In the last 2 years, she has consulted with or received speaker honoraria from Helsinn, Amgen, and Novartis (<US $10,000). E.B. has disclosed no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Amy P. Abernethy, MD, Duke University Medical Center, Box 3436, Durham, NC 27710. E-mail: [email protected].